Fractional dynamics pharmacokinetics–pharmacodynamic models by Verotta, Davide
Fractional dynamics pharmacokinetics–
pharmacodynamic models
Davide Verotta
Received: 17 February 2010/Accepted: 21 April 2010/Published online: 9 May 2010
  The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract While an increasing number of fractional order integrals and differential
equations applications have been reported in the physics, signal processing, engi-
neering and bioengineering literatures, little attention has been paid to this class of
models in the pharmacokinetics–pharmacodynamic (PKPD) literature. One of the
reasons is computational: while the analytical solution of fractional differential
equations is available in special cases, it this turns out that even the simplest PKPD
models that can be constructed using fractional calculus do not allow an analytical
solution. In this paper, we ﬁrst introduce new families of PKPD models incorpo-
rating fractional order integrals and differential equations, and, second, exemplify
and investigate their qualitative behavior. The families represent extensions of
frequently used PK link and PD direct and indirect action models, using the tools of
fractional calculus. In addition the PD models can be a function of a variable, the
active drug, which can smoothly transition from concentration to exposure, to
hyper-exposure, according to a fractional integral transformation. To investigate the
behavior of the models we propose, we implement numerical algorithms for frac-
tional integration and for the numerical solution of a system of fractional differential
equations. For simplicity, in our investigation we concentrate on the pharmacody-
namic side of the models, assuming standard (integer order) pharmacokinetics.
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Since Leibniz’s prophecy in the late seventeenth century to a few decades ago,
expressions involving fractional derivatives, integrals and differential equations
were mostly restricted to the realm of mathematics. The ﬁrst modern examples of
applications can be found in the classic papers by Caputo [1] and Caputo and
Mainardi [2] dealing with the modeling of viscoelastic materials, but it is only in
recent years that it has turned out that many phenomena can be described
successfully by models using fractional calculus. In physics fractional derivatives
and integrals have been applied to fractional modiﬁcations of the commonly used
diffusion and Fokker–Planck equations, to describe sub-diffusive (slower
relaxation) processes as well as super-diffusion [3]. Other examples are of
applications are in diffusion processes [4], signal processing [5], diffusion
problems [6]. More recent applications are mainly in physics: ﬁnite element
implementation of viscoelastic models [7], mechanical systems subject to
damping [8], relaxation and reaction kinetics of polymers [9], relaxation in
ﬁlled polymer networks [10], viscoelastic materials [11], although there are
recent applications in splines and wavelets [12, 13], control theory [14, 15], and
biology [16] (bacterial chemotaxis). Surveys with collections of applications can
also be found in Nonnenmacher and Metzler [17], and Podlubny [18]. The
suggestion of possible PK applications is reported in [19, 20], and generalized
in [21], while, to the best of our knowledge, there are no applications to
pharmacodynamics.
The reasons for the lack of application to pharmacodynamics are mainly two:
ﬁrst and foremost, PKPD models incorporating fractional calculus have not been
proposed; second, it turns out that one needs to provide special algorithms to deal
with such models. In this paper we propose new families of PKPD models
incorporating fractional calculus, and investigate their behavior using purposely
written algorithms. The main purpose of this paper is to attract the attention of the
ﬁeld into these possibly interesting families of PKPD models.
The structure of this paper is as follows. In the next section we brieﬂy recall the
mathematical foundations of fractional calculus, and summarize the algorithms for
the numerical methods used in the solution of problems described by fractional-
order integrals, and differential equations. We then provide illustrations of the
application of fractional order integrals, and systems of fractional order differential
equations PKPD models. In particular, we will focus on link models, direct
concentration–response relationships describing models relating drug concentration
(in plasma or biophase) to a pharmacodynamic effect, and indirect mechanism of
action models that involve primarily drug induced modulation of endogenous
factors. A ﬁnal discussion comments on the results, the general families of models
we introduce, and the challenges associated with the application of the models to
real data. A ﬁrst appendix provides (simpliﬁed) code for the implementation of the
numerical methods used in the paper, while a second appendix describes some
numerical properties of fractional integration which might help in the interpretation
of applications to PD data.
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The calculus of fractional integrals and derivatives is almost as old as calculus itself
going back as early as 1695, to a correspondence between Gottfried von Leibnitz
and Guillaume de l’Ho ˆpital. About 300 years had to pass before what is now known
as fractional calculus was slowly accepted as a practical instrument. A brief history
of the development of fractional calculus can be found in Miller and Ross [22],
while a survey of many emerging applications of the fractional calculus in areas of
science and engineering can be found in the text by Podlubny [23], here we give a
brief overview.
Although mathematical modelers dealing with dynamical systems are very
familiar with derivatives of integer order,
dmy
dxm; and their inverse operation,
integrations, they are generally much less so with fractional-order derivatives, for
example
d
1
3y
dx
1
3: One way to formally introduce fractional derivatives proceeds from the
repeated differentiation of an integer power p:
dm
dxmxp ¼
p!
ðp   mÞ!
xp m ð1Þ
For p a real number, repeated differentiation gives
dm
dxmxd ¼
C d þ 1 ðÞ
Cðd   m þ 1Þ
xd m ð2Þ
where the gamma functions [24] replace the factorials. The gamma function allows
for a generalization to a non-integer order of differentiation, with a real, a 0
da
dxaxd ¼
C d ðÞ
Cðd   a þ 1Þ
xd a ð3Þ
The extension deﬁned by Eq. 3 corresponds to the Riemann–Liouville derivative
[4, 22].
A more elegant and general way to introduce fractional derivatives uses the fact
that the m-th derivative is an operation inverse to m-fold repeated integration. Basic
to the deﬁnition is the integral identity
Zx
a
Zy1
a
   
Z ym 1
a
fy m ðÞ dym    dy1 ¼
1
ðm   1Þ!
Zx
a
x   y ðÞ
m 1fðyÞdy ð4Þ
Clearly, the equality is satisﬁed at x = a, and it is not difﬁcult to see iteratively that
the derivatives of both sides of the equality are equal. A generalization of the
expression allows the deﬁnition of a fractional integral (FI) of arbitrary order via
Ja
afðxÞ¼
1
C a ðÞ
Zx
a
x   y ðÞ
a 1fðyÞdy ð5Þ
where again the gamma function is replacing the factorial. In this paper we are
concerned with fractional time derivatives, and we take the lower limit in Eq. 5 to
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of the operators we consider, and use t, instead of x, to indicate the independent
variable time. Starting from Eq. 5, one can construct several deﬁnitions for frac-
tional differentiation. The fractional differential operator D
a
N is deﬁned by
D
a
N fðtÞ ¼
def
Jm aDmfðtÞð 6Þ
where m is the smallest integer greater than a, Dm ¼ dm
dxm (m integer) is the classical
differential operator, and f(t) is required to be continuous and a-times differentiable
in t. The operator D
a
Nis named after Caputo [1], who was among the ﬁrst to use it in
applications and to study some of its properties. It can be shown that the Caputo
differential operator is a linear operator, i.e. that for arbitrary constants a and b:
D
a
N afðtÞþbgðtÞ ðÞ ¼ aD
a
N fðtÞþbD
a
NgðtÞð 7Þ
which is important in PK and PD applications to, e.g., preserve linearity in respect to
inputs; that it commutes:
D
a
ND
b
NfðtÞ¼D
b
ND
a
NfðtÞð 8Þ
which is important to compute partial derivatives in respect to parameters for model
ﬁtting, or for future applications involving mixed effect models [25]; and that, as the
standard differential operator, it possesses the desirable property that:
D
a
Nc ¼ 0 ð9Þ
for any constant c, e.g. the Caputo derivative for steady-state values is zero, as it
should for physical realism.
Having deﬁned D
a
N; we can now turn to fractional differential equations (FDE),
and systems of FDE, which will be used to specify PKPD models and will need
to be solved over an interval [0,t], in accordance with appropriate initial conditions.
A FDE of the Caputo type has the form
D
a
NyðtÞ¼fðt;yðtÞÞ; ð10Þ
where y(t) is a vector of dependent state variables, and f(t,y(t)) a, dimensionally
conforming, vector valued function, satisfying a set of (possibly inhomogeneous)
initial conditions for the y(t) and its derivatives
Dky 0 ðÞ ¼ y k ðÞ
0 ; ð11Þ
k ¼ 0;...;a ~where a ~is the ceiling function, giving the smallest integer greater than
or equal to its argument. It turns out that under some very weak conditions placed on
the function f of the right-hand side of Eq. 10, a unique solution to Eqs. 10 and 11
does exist [26].
A typical feature of differential equations (both classical and fractional) is the
need to specify additional conditions in order to produce a unique solution. For the
case of Caputo FDE, these additional conditions are just the initial conditions listed
in Eq. 11 which are similarly required by classical ODEs. In contrast, for Riemann–
Liouville FDE, these additional conditions constitute certain fractional derivatives
(and/or integrals) of the unknown solution at the initial point t = 0[ 27], which are
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how such quantities are to be measured from experiment, say, so that they can be
appropriately assigned in an analysis [22]. If for no other reason, the need to solve
FDE is justiﬁcation enough for choosing Caputo’s deﬁnition for fractional
differentiation over the more commonly used (at least in mathematical analysis)
deﬁnition of Liouville and Riemann, and this is the operator that we choose to use in
the following.
Numerical approximation of caputo-type derivatives
One of the main factors limiting the applications of fractional order integrals, and
differential equations to the modeling of real data is the fact that analytic solutions
to equations of the form (5) and (10)–(11) are know only in simple cases, or for
speciﬁc values of a, see for example [28, 29]. As a consequence one is forced to use
numerical approximations to obtain the desired solutions. However, to date,
algorithms to do so have been developed only to a rather limited extent, and none is
available either commercially or as free software. To investigate the applications of
FI and FDE to PK/PD models we implemented numerical methods reported as
algorithms by [30, 31]. As indicated above, the natural concept for the fractional
integral to be used in connection with Caputo differential equations is the Riemann–
Liouville FI described in Eq. 5, and, as we will see, Riemann–Liouville integrals
will have applications in PKPD models. We therefore implemented an algorithm for
the solution of FI problems, which employs a product integration technique based
on the trapezoidal quadrature rule. That is, one replaces the given function f(t)b ya
piecewise linear interpolant, and then we calculate the resulting integral exactly.
The algorithm is also part of the numerical solution of FDE, which is of the Predict–
Evaluate–Correct–Evaluate type and is reported in simpliﬁed form the Appendix 1
as R code [32]. Appendix 2 shows some properties of the integration algorithm and
fractional integrals, and we refer to [30, 31] for further details. Other numerical
algorithms exist that solve FDE, e.g., [23, 33], but they focus on solving Riemann–
Liouville FDE and usually restrict the class of FDE to be linear with homogeneous
initial conditions, the algorithm reported in the appendix solves non-linear Caputo
differential equations with inhomogeneous initial conditions, if required. The
computations reported in this article are done using a tolerance of 0.001 (see
Appendix 1).
Fractional Integrals, Ja; and Caputo differential equations, D
a
N; are the operators
which are used to generalize the standard PKPD models, as described below.
Pharmacokinetics–pharmacodynamics models
A pharmacodynamic model is traditionally divided in two parts: a link model and a
transduction model (see [34] for a detailed description and review of pharmaco-
dynamic models). The link model describes the distribution of drug from an
observed compartment (e.g. plasma) into a biophase (the ‘‘effect compartment’’).
Drug in the biophase induces a pharmacodynamic response (the ‘‘effect’’), which is
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models: direct-response and indirect-response. In the case of direct response
models, the effect is represented by a non-linear memory-less function of drug
concentration in the effect site (Ce, the model was introduced by [35]). For indirect
action models the action of drug is also represented by a non-linear memory-less
function of Ce, in this case acting on the rate of production or elimination of an
endogenous substance (the effect) [36]. See [34] for a detailed description and
review of pharmacodynamic models.
In the following we assume that drug kinetics in plasma are represented by
standard (integer order) differential equation models, or their analytical solutions.
Link model
The model describing the transfer of drug to the effect compartment is, it its
mechanistic interpretation, part of the pharmacokinetics of the drug. However, in
practise, and because drug concentration in the effect compartment is not observed,
it is often unclear if the link model is actually associated with a site of action, or if it
represent some pharmacodynamic related delay, or a combination of the two. We
start by representing drug concentration in the effect compartment by the (Caputo)
fractional differential equation:
D
a
NCeðtÞ¼keo  CeðtÞþfðtÞ ðÞ ; Ceð0Þ¼Ce0 ð12Þ
where fðtÞrepresents the drug input into the central compartment and keo is the
elimination rate constant from the effect compartment. In general the solution of
Eq. 12 takes the form of the convolution:
CeðtÞ¼Ce0HðtÞþkeo
Zt
0
HðsÞfðt   sÞds ð13Þ
where HðtÞ¼Ea  keota ðÞ ; and Ea z ðÞ is the Mittag–Lefﬂer function [37]:
Ea z ðÞ¼
X 1
i¼0
zi
C ai þ 1 ðÞ
ð14Þ
The Mittag–Lefﬂer function is related to the monoexponential by the relationship
ez ¼
P 1
i¼0
zi
i! ¼
P 1
i¼0
zi
C iþ1 ðÞ ¼ E1 z ðÞ ; and it represents the unit-response function for
fractional kinetics (see [21] for general expressions of the unit-response functions
for arbitrary fractional compartmental structures).
Note that when Ce0 = 0, lim
keo!þ1
CeðtÞ¼fðtÞ; as for the standard effect
compartment model, but it also holds lim
a!0
CeðtÞ¼fðtÞ; a fact that might induce
a-posteriori identiﬁability problems.
In the following example fðtÞ¼ Doseka
Vk el ka ðÞ e kelt   e kat   
represents drug concen-
tration in the central compartment following, e.g., an oral administration of a dose
Dose; in the example Dose = 1, the initial condition in the effect compartment is
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upper panel of Fig. 1 shows concentration in the effect compartment for a = 1
(thick solid line, computed using the analytic solution to model (12)), and the
solution obtained using the predictor–corrector algorithm (superimposed thin solid
line, indistinguishable from the analytic solution). The additional dashed lines show
the solution to model (12) with a = 0.9, 0.75, 0.5, and 0.25, computed using the
predictor–corrector algorithm. One can notice the delay in the peak concentration of
Ce(t) (time to peak concentration, tpeak, is at 1.63 (unit time, ut)) versus Cp
(tpeak = 0.50 ut), delay that shortens as a decreases (tpeak = 1.47, 1.28, 0.97, 0.69
ut). In addition the decline is slower than exponential. The lower panel of Fig. 1
shows Ce(t) proﬁles for a = 1, 0.25, 0.01, 0.001, 0.0001, and 0.00001. Following
the proﬁles for decreasing values of a, note the change of Ce(t) from initial
convexity to concavity, and its progressive approach to the proﬁle of drug
concentration in plasma (Cp(t), thick dashed line), which is exactly reached for
a = 0.0, when HðtÞ¼d t ðÞ ; the Dirac delta-function. A feature of the family of
curves corresponding to a\0.01 is that tpeak in the effect comportment is earlier
than in the central compartment: tpeak is approximately equal to 0.48, 0.32, 0.45, for
a = 0.01, 0.001, 0.0001, respectively, tpeak = 0.50 for a = 0.00001.
Direct action models
In the standard direct action model the effect at time t, YðtÞ; is expressed by an
arbitrary (memory-less) function of drug concentration in the effect site at time
t; G CeðtÞ ðÞ ; however to generate a wider class of relationships, we assume that the
effect at time t is related to the Riemann–Liouville fractional integral of Ce(t), a
quantity that we call acting drug:
AðtÞ¼JbCeðtÞ: ð15Þ
For a direct action model the effect is simply related to A(t) by a non-linear
memory-less function G:
YðtÞ¼GA ðtÞ ðÞ : ð16Þ
Equation 16 for b = 0 represents a standard direct action model, the acting drug is
drug concentration in the effect site: YðtÞ¼GC e ðtÞ ðÞ ; for b = 1 it represents an
effect related to the exposure,
R t
0
CeðtÞdt, where YðtÞ¼G
R t
0
CeðtÞdt
  
; for 0\b\1
the effect is related to a fractional integral that is in between Ce(t) and exposure, i.e.,
it represents effects depending on hypo-exposure to drug, for b[1 we have the
cases of hyper-exposure dependencies.
The upper panel of Fig. 2 shows JbCeðtÞ; where Ce(t) is computed as before
(a = 0, i.e. the effect compartment has ﬁrst order kinetics) for different values of b,
using the numerical approximation to Riemann–Liouville integrals. Note that
lim
t!1JbCeðtÞ¼0 for b\1, while for b = 1 lim
t!1JbCeðtÞ¼Dose.
The lower panel of Fig. 2 shows the corresponding effect proﬁles when:
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¼ E0 þ
Emax JbCeðtÞ
  
Ce50 þ JbCeðtÞ
   ð17Þ
and E0 = 0.1, Emax = 1, Ce50 = 0.15. Note how for b = 0, 0.1, 0.3, 0.6, and 0.9
the effect return to baseline, lim
t!þ1Yðt) = E0, but the return is progressively delayed.
For b = 1, the effect, reaches the maximum E0 þ EmaxDose
Ce50þDose, and does not return to
baseline.
The upper panel of Fig. 3 shows JbCeðtÞ for b = 1, 1.25, 1.5, 1.75, 2.0, i.e., cases
in which the effect is either proportional or hyper-proportional to exposure to drug.
In the upper panel, note how the Riemann–Liouville fractional integration
Fig. 1 Numerical solutions to the link model equation (12) versus time (t). Da
t CeðtÞ¼
keo  CeðtÞþfðtÞ ðÞ ,C e(0) = Ce0, f(t)= Doseka
Vk el ka ðÞ e kelt   e kat   
, for different values of a (see text for
parameters values). Upper panel (thick solid line): analytic solution for a = 1, thin solid line:
indistinguishable from the analytic solution: numerical solution for a = 1; dashed lines: numerical
solutions for a = 0.9, 0.75, 0.5, and 0.25, as for the legend in the ﬁgure. Lower panel (dashed lines)
numerical solutions for a = 0.25, 0.01, 0.001, 0.0001, 0.00001; thick dashed line: f(t) (concentration in
the central compartment)
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b = 1, A(t) asymptotes to Dose, that is lim
t!þ1
A(t) = Dose, for b[1w e
have lim
t!þ1A(t) = + 1. The lower panel of Fig. 3, shows the effect proﬁles
computed according to (17), where now, for b[1, lim
t!þ1Yðt) = E0 þ Emax.
Indirect action models
Dyneka et al. proposed four indirect response models [36] that are based on drug
(Cp(t)o rCe(t)) effects that either stimulate or inhibit the production or loss of an
effect (or its mediator). The models take the form:
Fig. 2 Numerical solutions to the direct action model equation (16) versus time (t).
YðtÞ¼GJ bCeðtÞ
  
¼ E0 þ
Emax JbCeðtÞ ½ 
Ce50þ JbCeðtÞ ½  , Ce(t) computed as in Fig. 1. Upper panel: numerical solutions
to JbCeðtÞ for b = 0( J0CeðtÞ¼CeðtÞ, i.e. drug concentration in the effect compartment), b = 0.1, 0.3,
0.6, 0.9 (i.e. hypo-exposure), b = 1( J1CeðtÞ¼
R t
0
CeðtÞdt, exposure to drug concentration in the effect
compartment). Lower panel: YðtÞ¼GJ bCeðtÞ
  
for the same values of b
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dt
¼ kin 1   GC e ðtÞ ðÞ ðÞ   koutYðtÞ; Yð0Þ¼kin=kout ð18Þ
where kin and kout are the production and elimination rate of Y(t), and, G(Ce(t))
positive drug stimulates or inhibits the production rate depending on the sign in the
equation; or
dYðtÞ
dt
¼ kin   kout 1   GC e ðtÞ ðÞ ðÞ YðtÞ; Yð0Þ¼kin=kout ð19Þ
where drug stimulates or inhibits the elimination rate of Y(t). Fractional dynamics
can be immediately introduced by substituting JbCeðtÞ,o rJbCpðtÞ, for Ce(t)i n
Eq. 18. However, an additional alternative class of models is generated if we make
Fig. 3 Numerical solutions to the direct action model equation (16) versus time (t). Upper panel:
numerical solutions to JbCeðtÞ, for b = 1, exposure to drug concentration in the effect compartment, for
b = 1.25, 1.5, 1.75, hyper-exposure, and for b = 2 quadratic exposure, J2CeðtÞ¼
R t
0
R t
0
CeðtÞdtds. Lower
panel: YðtÞ¼GJ bCeðtÞ
  
for the same values of b
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consider an inhibition of production rate:
Dd
NYðtÞ¼kin 1   GC e ðtÞ ðÞ ðÞ   koutYðtÞ; Yð0Þ¼kin=kout ð20Þ
when kin = 1, kout = 1, GC e ðtÞ ðÞ ¼
EmaxCeðtÞ
Ce50þCeðtÞ, Ce(t) is as in the previous examples.
The upper panel of Fig. 4 shows the effects proﬁles corresponding to model (20),
for 0\d 1. The main features are the quicker onset and slower decay when
0\d\1, dashed lines, in respect to the standard model d ¼ 1, solid line. The lower
panel of Fig. 4 shows effects proﬁles for 1 d\2. Now when 1\d\2the onset of
the effect is delayed, and damped oscillations are introduced on the way to the
return to baseline kin/kout = 1.
Fig. 4 Numerical solutions to the indirect action model equation (20) versus time (t).
Dd
NYðtÞ¼kin 1   GC e ðtÞ ðÞ ðÞ   koutYðtÞ, Yð0Þ¼kin=kout, GC e ðtÞ ðÞ ¼
EmaxCeðtÞ
Ce50þCeðtÞ, Ce(t) computed as in
Fig. 1 (see text). Upper panel (solid line): Y(t) corresponding to the standard indirect action model,
d = 1; dashed lines: Y(t) corresponding to the fractional differential equation solved for 0\d\1.
Lower panel (solid line): Y(t) for d = 1; dashed lines: Y(t) for 1\d\2
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inhibition of elimination rate:
Dd
NYðtÞ¼kin   kout 1   GC e ðtÞ ðÞ ðÞ YðtÞ; Yð0Þ¼kin=kout ð21Þ
where all the parameters are as in Fig. 4, but GC e ðtÞ ðÞ ¼
Emax CeðtÞ ½ 
c
Ce
c
50þ CeðtÞ ½ 
c with c = 2.
Note how in Fig. 4 and 5 the Y(t) can take negative values, indicating that,
depending on the application, c will need to be constrained to satisfy the physical
properties of the response.
The main observations that can be derived from the examples so far reported as
well as additional extensions are discussed below.
Fig. 5 Numerical solutions to the indirect action model equation (21) versus time (t).
Dd
NYðtÞ¼kin   kout 1   GC e ðtÞ ðÞ ðÞ YðtÞ, Yð0Þ¼kin=kout, GC e ðtÞ ðÞ ¼
Emax CeðtÞ ½ 
c
Ce
c
50þ CeðtÞ ½ 
c, Ce(t) computed as in
Fig. 1 (see text). Upper panel (solid line): Y(t) for d = 1; dashed lines: Y(t) for 0\d\1. Lower panel
(solid line): Y(t) for d = 1; dashed lines: Y(t) for 1\d\2
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Fractional calculus has only recently came to the attention to pharmacokinetics
modelers. The use of the Mittag–Leffner function, instead of a monoexponential, to
describe single-compartment kinetics following bolus input was suggested in [19],
[20] extends the approach to commensurate
1 two compartmental models, while [21]
points out that certain sums of single- and two-parameters Mittag–Lefﬂer functions
turn out to be the response functions corresponding to rather arbitrary, commen-
surate and non-commensurate, compartmental systems [21], those sums, and their
convolution with arbitrary inputs, can be used to represent a very large class of
fractional pharmacokinetics models.
This paper turns the attention to pharmacodynamics, and in so doing it introduces
a new approach to pharmacodynamics modeling using fractional integrals and
fractional differential equations. The approach not only extends well-known direct-
and indirect-action models, but also generates novel families of PD models, which
are reported, for easy reference and summary, in Table 1. The models we propose
offer mechanistic insight very similar to the ordinary ones, and in particular models
parameters, other than the fractional orders, allow the same interpretation.
The examples reported above are speciﬁc instances of these families: Fig. 1
shows the link models when a varies; Fig. 2 and 3 direct action models for a = 1,
b variable, and d = 1; Fig. 4 and 5 indirect action models for a = 1, b = 1, and
d variable. We now comment further on the models we introduce.
Table 1 Fractional calculus based link, active drug, and pharmacodynamics models
Direct action Indirect action
Link D
a
NCeðtÞ¼keo  CeðtÞþfðtÞ ðÞ
Active drug
AðtÞ¼JbCeðtÞ
Concentration b ¼ 0
AðtÞ¼CeðtÞ
Hypo-exposure 0\b\1
Exposure b ¼ 1
AðtÞ¼
R t
0
CeðtÞdt
Hyper-exposure 1\b 2
Pharmacodynamics
YðtÞ¼JdGA ðtÞ ðÞ
Dd
NYðtÞ¼kin 1   GA ðtÞ ðÞ ðÞ   koutYðtÞ
Dd
NYðtÞ¼kin   kout 1   GA ðtÞ ðÞ ðÞ YðtÞ
1 A system of m fractional differential equations is said to be commensurate when each FDE is of the
same fractional order, a; non-commensurate when the fractional orders, a1, a2, …, am, are distinct for
each equation. For the PD models we propose a, b, and d can be distinct.
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In addition to possible additional variety of kinetics for the effect compartment
introduced by the use of Eq. 12, the observed behaviour of the link models (Fig. 1)
suggest a possible application to situations in which the observed peak effect is
observed earlier than the peak concentration. The example of nicotine effect on
heart rate represents one of these possible applications [38].
Direct action models
The main novelty demonstrated by Fig. 2, is the introduction of what we call
‘‘active drug’’, the fractional integral of the concentration in the effect compartment.
The active drug serves as independent variable for the pharmacodynamic model,
and this, as shown by Eq. 16 and Fig. 2, allows the deﬁnition of a large family of
models. The models smoothly range from a standard dependency on Ce(t)( b = 0),
to dependency on hypo-exposure (0\b\1), to a standard exposure model
(b = 1), and dependency on hyper-exposure (b[1). The family generated by
varying b potentially greatly expands the current possibilities, limited to b = 0o r1 ,
in addition this is achieved using the simplest tool of fractional calculus (fractional
integration). Hypo-exposure models are particularly interesting because they
establish a relationship with integrals of drug concentrations, but they are
reversible: for 0\b\1 eventually the effect returns to baseline when drug is
eliminated from the body, thus this feature removes one of the main limitations of
models depending on exposure. Hyper-exposure models are, as well as exposure
models, not reversible, but they might have applications, for example in toxicity
studies. (Appendix 2 further comments on the properties of fractional integration in
its relationship to the concept of ‘‘active drug’’ and hypo-/hyper-exposure models.)
Indirect action models
The use of fractional dynamics as in models (20) and (21), allows to smoothly
transition from models with exponential or sub-exponential tails (0\a 1), to
models showing damped-oscillations (1\a\2). The latter could offer interesting
applications to effects exhibiting rebound and (damped) oscillatory return to
baseline, possibly avoiding the formulation or more complicated models describing
such behaviours.
Setting a = 1, but using active drug, AðtÞ¼JbCeðtÞ, instead of Ce(t), introduces
a family of models similar to the direct action model described by Eq. 16, one that
was not considered in the examples reported above.
General considerations
As one reviewer pointed out ‘‘a great beneﬁt for the methods proposed is increase
ﬂexibility of response-time proﬁles with only a slight expenditure in the number of
parameters. That is, the FDE approach appears to lend itself to parsimony. The
value of this ﬂexibility is appealing, especially if one considers PKPD models
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also pointed out that it would be useful to relate the FDE approach to a mechanistic
model. For example, the use of a Mittag–Leffner function, instead of a mono-
exponential, can be conceptually related to more complicated diffusion processes
than traditionally assumed [3]. For the PD models we introduce, the same argument
can be made for the FDE link model, while for the FDE extension of direct/indirect-
action models one might associate the FDE representations to more complicated
binding or transduction processes. It is also possible that the models transitioning
into damped-oscillations (1\a\2) could be used to as lamped approximation to
feed-back type processes. Fractional exposure models have possibly the simplest
explanation, representing a very natural generalization of traditional exposure
models. Mechanistically a fractional exposure model might be generated, for
example, in presence of modulation of excretory transport [39].
Open problems and questions
The main problem to solve to apply the models we present in this paper to real data
is the development of ﬂexible algorithms that can be used in conjunction with an
estimation program such as NONMEM [40] or NLME [41] for model identiﬁcation.
In particular the algorithm used here [30] will need to be modiﬁed to allow for non-
equispaced observations as well as to allow for multiple fractional components. We
are collaborating with Prof. Kai Diethelme and Neville Ford to develop more robust
and ﬂexible FI and FDE numerical solvers.
As the examples reported in this paper demonstrate, the behaviour of FI and
especially FDE are quite sensitive to small variations in a, and this sensitivity might
pose problems when estimating a as well as the other parameters of a PKPD model.
The usual identiﬁability issues [42], and the use of constraints will need to be
investigated as well.
It is quite obvious, in reference to Table 1, that one could devise more
complicated examples than the ones shown and discussed above: PKPD models are
well deﬁned for any combination of a, b, and d. (For example, for a direct action
model setting a,b = 1, but d variable, introduces yet another family in which the
effect is related to a fractional integral of the function GC e ðtÞ ðÞ :) While the
ﬂexibility provided by the possible choices in a, b, and d should offer a rich and
interesting family of models, practical problems could arise simply due to the large
number of models that would need to be considered. For example, should one adopt
fractional components for only a part of the overall model (as we did in the
examples), simultaneously considers fractional pharmacokinetics, link, active drug
and pharmacodynamics? A similar situation, an embarrassment of riches, was ﬁrst
encountered when direct and indirect action models were introduced, and the need
for model discrimination arose as a consequence of the novel, larger, class of PKPD
models [43]. In addition, there are of course a much larger number of PD models
used in the literature [34] than the basic classes we considered here. Tolerance and
feedback models might be in particular potentially useful candidates for the
application of fractional dynamics.
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on the application of fractional calculus to PKPD models. The aim of the paper
is not to claim the superiority of fractional dynamics models is respect to
standard ones, but it is simply to deﬁne the new families, and provide some
insights into their qualitative behaviour. The main purpose is to suggest possible
applications and stimulate further research, which might, or might not,
demonstrate the applicability and importance of PKPD models based on
fractional calculus.
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Appendix 1
We report the algorithm used to solve the FDE in the examples reported above. The
algorithm (FSDEs) is implemented in R [32], and follows the derivation reported in
[30, 31]. Both the FI and FDE algorithms are available from the author upon
request.
Input variables
f = a p-valued function of p ? 1 real variables that deﬁnes the right-hand side of
the differential equation (10).
b (beta) = a vector of parameters used in the function f.
a (alpha) = the order of the system of FDE (a positive real number).
tol = the precision required in the solution.
y0 = an array of dimension p   a ~, containing the initial values yjkð0Þ;
j ¼ 1;...;a ~, k ¼ 1;...;p.
xmax = the upper bound of the interval where the solution is to be approximated
(a positive real number).
n = the number of time steps that the algorithm is to take (a positive integer).
Main internal variables
a, b = arrays of n ? 1 real numbers that contain the weights of the corrector and
predictor formulae, respectively.
Output variables
xc = an array of dimension n that contains the times at which the approximate
solutions to Eq. 10 is computed.
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fsdes\- function(alpha = 1, y0, beta, xmax = 1, tol = 0.001){
n\-ceiling(xmax/(sqrt(tol*xmax)))
xc\-(seq(from = 0, to = xmax, length = n?1))
h\-xc[2]-xc[1] # h = the step size of the algorithm
m\-nrow(y0)
ca\-ceiling(alpha)
mult\-(h**alpha)/gamma(alpha ? 2)
b\-a\-rep(0, n ? 1)
yc\-matrix(0, nrow = m, ncol = n?1)
# assign the weights for 0\n\N
for (k in 1:(n ? 1)){
b[k]\-k**alpha-(k-1)**alpha
a[k]\-(k ? 1)**(alpha ? 1)-2*(k)**(alpha ? 1) ? (k-1)**(alpha ? 1)
}
# Body of procedure
yc[,1]\-y0[,1]
for (j in 1:n){
p1\-p2\-0
for (k in 0:(ca-1)){
p1\-p1 ? (j*h)**k/(factorial(k))*y0[,k ? 1]
}
for (k in 0:(j-1)){
p2\-p2 ? b[j-k]*model(xc[k ? 1],yc[,k ? 1],beta)
}
p\-p1 ? p2*(h**alpha)/gamma(alpha ? 1)
yc1\-yc2\-yc3\-yc4\-0
for (k in 0:(ca-1)){
yc1\-yc1 ? (j*h)**k/(factorial(k))*y0[,k ? 1]
}
yc2\-model(xc[j ? 1], p, beta) # predictor: weight 1
yc3\-model(0, y0[,1],beta)*((j-1)**(alpha ? 1)-(j-1-alpha)*j**alpha)
if (j[1) {for (k in 1:(j-1)){
yc4\-yc4 ? a[j-k]*model(xc[k ? 1],yc[,k ? 1],beta)
}}
yc[,j ? 1]\-yc1 ? (yc2 ? yc3 ? yc4)*mult
}
list(x = xc,y = yc)
}
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solutions to Eq. 10, zjk;k ¼ 1;...;p; j ¼ 1;...;n
Appendix 2
We discuss some the properties of the numerical approximation to the Riemann–
Liouville integral with particular regard to its relationship with the active drug
component the PD models we propose, see Eq. 15 and Table 1.
Figure 6 shows a visualization of the quadrature weights used for fractional
integration (similar weights are used for the predictor in the FDE). The line
segments displayed represent scaled weights (to retain an easy interpretation of the
results), averaged over each subinterval of integration, for an arbitrary integration
interval. For b = 1, i.e., JbCeðtÞ¼
R t
0
CeðtÞ dt, the average weight is constant,
showing how the algorithm reduces to classic trapezoidal integration. Previous drug
concentrations are simply ‘‘summed’’ to obtain the exposure to drug. However, as
pointed out in [26] there is a quite striking difference for the cases 0\b\1 and
1\b\2.
Fig. 6 Scaled weights of quadrature for the numerical approximation of the Riemann–Liouville
fractional integral (Eq. 5) and active drug AðtÞ¼JbCeðtÞ)
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solution than the more recent ones, that is fractional integration exhibits a long-term
memory loss in respect to standard integration, and the smaller the value of b the
greater the degree of long-term memory loss. In terms of PD models 0\b\1
corresponds to hypo-exposure models, and the weights indicate how recent drug
concentrations contribute more to the value of ‘‘active drug’’ than previous ones; to
the limit when b = 0, i.e., JbCeðtÞ¼CeðtÞ, the effect only depends on current drug
concentration, so that for a direct action model we are back to the standard memory-
less relationship between effect and concentration in the effect compartment.
In contrast, when 1\b\2, the earlier values of the integrand will contribute
more to the overall solution than will the more recent ones. Fractional integration
therefore exhibits a short-term memory loss, in respect to standard integration.
Furthermore, the greater the value of b the more pronounced the short-term memory
loss will be. The case 1\b\2, corresponds to hyper-exposure PD models,
providing a representation in which the most recent drug concentrations are less
important than the concentrations at the beginning of the administration to
determine the effect.
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